How do you see the latest anti COVID drug launch by Reddy Labs?
Answer
Answer
Dr Reddy's Laboratories announced the launch of Avigan, which is a generic version of Favipiravir, used for mild COVID to moderate COVID-19 symptoms. The formulation will be launched in the form of 200 mg tablets in India for treatment of patients.
Japan based Fujifilm Toyama Chemical, one of the world’s leading pharma brands, has granted Reddy Labs exclusive rights to manufacture, to sell and to distribute Avigan tablets in India. It be recollected that Avigan has already been approved by the DCGI.
Dr Reddy's Avigan comes in a complete therapy pack of 122 tablets having a two-year shelf life. It works best for mild to moderate symptoms and can also be taken as a preventive.